Literature DB >> 10220449

Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid.

J A Weiner1, J Chun.   

Abstract

Lysophosphatidic acid (LPA) is a bioactive phospholipid with properties of an extracellular growth factor for many cell lines, including those derived from neuroblastomas. However, the relevance of LPA signaling to the normal, developing nervous system is unknown, in part reflecting the previous unavailability of cloned receptor genes. Recent studies of the first such gene, encoding the G protein-coupled receptor LPA1/VZG-1 (lysophospholipid receptor A1/ventricular zone gene-1), revealed a major locus of expression in oligodendrocytes and Schwann cells (SCs) during development, suggesting an influence of LPA on these myelinating cells. Here we report that LPA (>/=10 nM) is a potent survival factor for cultured neonatal SCs, with survival activity equaling the maximal effect of neuregulin, the major peptide SC survival factor. LPA activates a pharmacologically defined signaling pathway in SCs, involving Gi and phosphoinositide 3-kinase. Moreover, LPA's effect depends on Akt, a downstream kinase that can mediate phosphoinositide 3-kinase-dependent survival, as demonstrated by both Western blot and transfection analyses. Overexpression of functional epitope-tagged LPA1/VZG-1 protein decreases SC apoptosis in response to serum withdrawal. These data demonstrate a role for extracellular LPA and its receptor LPA1/VZG-1 in SC survival and, more broadly, implicate G protein-coupled receptor-mediated lysophospholipid signaling as a significant mechanism in neural development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220449      PMCID: PMC21847          DOI: 10.1073/pnas.96.9.5233

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes.

Authors:  J C Louis; E Magal; D Muir; M Manthorpe; S Varon
Journal:  J Neurosci Res       Date:  1992-01       Impact factor: 4.164

2.  A role for the acetylcholine receptor-inducing protein ARIA in oligodendrocyte development.

Authors:  T Vartanian; G Corfas; Y Li; G D Fischbach; K Stefansson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

3.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium.

Authors:  M C Raff; R H Miller; M Noble
Journal:  Nature       Date:  1983 Jun 2-8       Impact factor: 49.962

4.  Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis.

Authors:  A H Wyllie; R G Morris; A L Smith; D Dunlop
Journal:  J Pathol       Date:  1984-01       Impact factor: 7.996

5.  The bioactive phospholipid lysophosphatidic acid is released from activated platelets.

Authors:  T Eichholtz; K Jalink; I Fahrenfort; W H Moolenaar
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

6.  Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve.

Authors:  J P Brockes; K L Fields; M C Raff
Journal:  Brain Res       Date:  1979-04-06       Impact factor: 3.252

7.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor.

Authors:  C A Milano; L F Allen; H A Rockman; P C Dolber; T R McMinn; K R Chien; T D Johnson; R A Bond; R J Lefkowitz
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Serum contains inducers and repressors of oligodendrocyte differentiation.

Authors:  L Bologa; R Cole; F Chiappelli; R P Saneto; J de Vellis
Journal:  J Neurosci Res       Date:  1988       Impact factor: 4.164

9.  Identification and purification of glial growth factor.

Authors:  G E Lemke; J P Brockes
Journal:  J Neurosci       Date:  1984-01       Impact factor: 6.167

10.  Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3.

Authors:  K L Carraway; S P Soltoff; A J Diamonti; L C Cantley
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

View more
  58 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  Identification of neural programmed cell death through the detection of DNA fragmentation in situ and by PCR.

Authors:  J Chun; A J Blaschke
Journal:  Curr Protoc Neurosci       Date:  2001-05

6.  The unfolded protein response is a major mechanism by which LRP1 regulates Schwann cell survival after injury.

Authors:  Elisabetta Mantuano; Kenneth Henry; Tomonori Yamauchi; Nobuhiko Hiramatsu; Kazuyo Yamauchi; Sumihisa Orita; Kazuhisa Takahashi; Jonathan H Lin; Steven L Gonias; W Marie Campana
Journal:  J Neurosci       Date:  2011-09-21       Impact factor: 6.167

7.  Blockage of lysophosphatidic acid signaling improves spinal cord injury outcomes.

Authors:  Yona Goldshmit; Rosalia Matteo; Tamar Sztal; Felix Ellett; Frisca Frisca; Kelli Moreno; Duncan Crombie; Graham J Lieschke; Peter D Currie; Roger A Sabbadini; Alice Pébay
Journal:  Am J Pathol       Date:  2012-07-20       Impact factor: 4.307

8.  Lysophosphatidic acid (LPA) and its receptor, LPA1 , influence embryonic schwann cell migration, myelination, and cell-to-axon segregation.

Authors:  Brigitte Anliker; Ji Woong Choi; Mu-En Lin; Shannon E Gardell; Richard R Rivera; Grace Kennedy; Jerold Chun
Journal:  Glia       Date:  2013-09-24       Impact factor: 7.452

9.  Development and biological evaluation of fluorophosphonate-modified hydroxyapatite for orthopaedic applications.

Authors:  Gráinne Neary; Ashley W Blom; Anna I Shiel; Gabrielle Wheway; Jason P Mansell
Journal:  J Mater Sci Mater Med       Date:  2018-07-21       Impact factor: 3.896

10.  The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein.

Authors:  Elisabetta Mantuano; Gen Inoue; Xiaoqing Li; Kazuhisa Takahashi; Alban Gaultier; Steven L Gonias; W Marie Campana
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.